Boardroom Alpha
Boardroom Alpha
LMAT · Current Report (Form 8-K) · Filed April 14, 2026

Lemaitre Vascular Inc — Current Report (Form 8-K)

Form
8-K
Filed
April 14, 2026
Period
Apr 8, 2026
Ticker
LMAT
Accession
0001193125-26-153779
Boardroom Alpha · Filing insights

Bridget Ross will not seek re-election. David Roberts nominated for Class II; board size to seven after the 2026 meeting.

About Lemaitre Vascular Inc
Market cap
$2.1B
1Y TSR
+23.3%
3Y TSR
+16.1%
Board grade
A-
Sector
Healthcare
CEO
George W Lemaitre
Last annual meeting: Jun 2, 2026 · View full Lemaitre Vascular Inc profile →
8-K
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(0)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 8, 2026

 

 

LeMaitre Vascular, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-33092   04-2825458
(Commission File Number)   (IRS Employer Identification No.)

 

63 Second Avenue  
Burlington, Massachusetts   01803
(Address of Principal Executive Offices)   (Zip Code)

(781) 221-2266

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common   LMAT   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On April 8, 2026, Bridget Ross notified the Board of Directors (the “Board”) of LeMaitre Vascular, Inc. (the “Company”) of her intent not to stand for re-election as a Class II director of the Company at the Company’s 2026 Annual Meeting of Stockholders to be held on June 2, 2026 (the “2026 Annual Meeting”). Ms. Ross will continue to serve as a director and a member of each committee of the Board to which she has been appointed until her current term expires at the 2026 Annual Meeting. Ms. Ross’s decision not to stand for re-election is not related to any disagreement with the Company on any matter relating to the operations, policies, or practices of the Company. The Board thanks Ms. Ross for her service and contributions during her tenure.

In order to rebalance the Board classes upon the expiration of Ms. Ross’s current term at the 2026 Annual Meeting, the Board nominated David B. Roberts to stand for election as a Class II director at the 2026 Annual Meeting. In connection with such nomination, on April 9, 2026, Mr. Roberts notified the Board of his intent to resign as a Class I director at the conclusion of the 2026 Annual Meeting, contingent upon his election as a Class II director at such meeting. Mr. Roberts’s decision to conditionally resign as a Class I director is solely to facilitate his election as a Class II director at the 2026 Annual Meeting and is not a result of any disagreement with the Company on any matter relating to the operations, policies, or practices of the Company. Upon the effectiveness of Ms. Ross’s departure, and assuming Mr. Roberts’s election as a Class II director, at the conclusion of the Annual Meeting the Board will consist of seven members, designated as two Class I directors, two Class II directors, and three Class III directors.

 

Item 8.01

Other Events.

The Company’s Second Amended and Restated Certificate of Incorporation and Second Amended and Restated By-laws provide that the size of the Board shall be determined from time to time by resolution of the Board. As a result of the events described in Item 5.02, the Board has taken action to reduce the size of the Board from eight to seven members, effective immediately upon Ms. Ross’s departure from the Board. In this regard, effective as of the conclusion of the 2026 Annual Meeting, and assuming Mr. Roberts is elected as a Class II director, the Board will eliminate the vacant Class I directorship resulting from the resignation of Mr. Roberts as a Class I director to facilitate his election as a Class II director.

Forward-Looking Statements

This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    LEMAITRE VASCULAR, INC.
Dated: April 14, 2026      
    By:  

/s/ Dorian P. LeBlanc

    Name:   Dorian P. LeBlanc
    Title:   Chief Financial Officer
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Lemaitre Vascular Inc (LMAT)

Reference

Frequently asked questions

When did Lemaitre Vascular Inc file this 8-K?
Lemaitre Vascular Inc (LMAT) filed this Current Report (Form 8-K) with the SEC on April 14, 2026. The accession number assigned by EDGAR is 0001193125-26-153779.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Bridget Ross will not seek re-election. David Roberts nominated for Class II; board size to seven after the 2026 meeting. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Lemaitre Vascular Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Lemaitre Vascular Inc has filed under CIK 1158895, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer